HC Wainwright Analysts Decrease Earnings Estimates for SXTP

60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) – Equities research analysts at HC Wainwright cut their Q4 2024 earnings per share estimates for shares of 60 Degrees Pharmaceuticals in a report released on Tuesday, February 25th. HC Wainwright analyst E. White now anticipates that the company will earn ($4.77) per share for the quarter, down from their prior forecast of ($4.75). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for 60 Degrees Pharmaceuticals’ current full-year earnings is ($5.09) per share. HC Wainwright also issued estimates for 60 Degrees Pharmaceuticals’ FY2025 earnings at ($3.59) EPS.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a research note on Wednesday, February 19th.

60 Degrees Pharmaceuticals Trading Down 6.5 %

SXTP opened at $1.88 on Thursday. The business’s 50 day moving average is $4.41 and its 200-day moving average is $5.52. The stock has a market cap of $2.77 million, a PE ratio of -0.19 and a beta of 4.22. 60 Degrees Pharmaceuticals has a twelve month low of $1.78 and a twelve month high of $35.99.

Insiders Place Their Bets

In related news, CEO Geoffrey S. Dow bought 7,164 shares of the business’s stock in a transaction on Monday, December 9th. The stock was bought at an average price of $6.35 per share, for a total transaction of $45,491.40. Following the transaction, the chief executive officer now directly owns 18,916 shares in the company, valued at $120,116.60. This represents a 60.96 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders bought a total of 12,073 shares of company stock worth $76,966 over the last ninety days. 10.27% of the stock is currently owned by company insiders.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.